Deuruxolitinib significantly improves scalp hair regrowth in alopecia areata
Deuruxolitinib was found to significantly improve scalp hair regrowth in alopecia areata, according to data from its Phase 3 clinical trial, THRIVE-AA2, presented at the American Academy of Dermatology’s (AAD) 2023 Annual Meeting Late Breaking News Session.
The primary efficacy endpoint of the trial was the percentage of patients achieving an absolute Severity of Alopecia Tool (SALT) score of ≤20 at week 24 of treatment compared to placebo. The new data showed that 21% of patients treated with 8 mg twice-daily and 35% of patients treated with 12 mg twice-daily of deuruxolitinib achieved near-complete or complete scalp hair regrowth, compared with 0% in the placebo group.
“We are pleased by the consistency of the Phase 3 results generated in the THRIVE-AA clinical program,” said James V. Cassella, PhD, Chief Development Officer of Concert in a press release. “Based on the strength of the THRIVE-AA2 data along with data from the THRIVE-AA1 trial and the continuation of our Breakthrough Therapy designation, deuruxolitinib has the potential to be a best-in class treatment option for alopecia areata. We look forward to filing our deuruxolitinib New Drug Application with the Food and Drug Administration next quarter and bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”
Read the full press release here.
